M&R Capital Management Inc. raised its position in shares of Shire PLC (NASDAQ:SHPG) by 2.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 26,907 shares of the biopharmaceutical company’s stock after buying an additional 706 shares during the quarter. M&R Capital Management Inc.’s holdings in Shire were worth $4,120,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in SHPG. YorkBridge Wealth Partners LLC raised its position in Shire by 81.7% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 705 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 317 shares during the last quarter. BB&T Investment Services Inc. grew its stake in shares of Shire by 1,672.3% during the 3rd quarter. BB&T Investment Services Inc. now owns 833 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 786 shares during the period. Pacer Advisors Inc. bought a new stake in shares of Shire during the 2nd quarter valued at about $171,000. Stephens Inc. AR grew its stake in shares of Shire by 22.2% during the 2nd quarter. Stephens Inc. AR now owns 1,256 shares of the biopharmaceutical company’s stock valued at $208,000 after purchasing an additional 228 shares during the period. Finally, Ingalls & Snyder LLC grew its stake in shares of Shire by 10.8% during the 2nd quarter. Ingalls & Snyder LLC now owns 1,284 shares of the biopharmaceutical company’s stock valued at $212,000 after purchasing an additional 125 shares during the period. 20.28% of the stock is owned by institutional investors and hedge funds.

A number of brokerages recently issued reports on SHPG. Jefferies Group reiterated a “hold” rating and set a $206.00 price objective (down from $216.00) on shares of Shire in a research note on Wednesday, August 9th. Barclays downgraded Shire from an “overweight” rating to an “equal weight” rating in a research note on Friday, August 11th. Cantor Fitzgerald set a $222.00 price objective on Shire and gave the company a “buy” rating in a research note on Tuesday, August 15th. Evercore ISI began coverage on Shire in a research note on Wednesday, August 16th. They set an “outperform” rating and a $196.00 price objective for the company. Finally, ValuEngine downgraded Shire from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the company. Shire currently has a consensus rating of “Buy” and an average price target of $212.18.

Shares of Shire PLC (NASDAQ:SHPG) traded down $1.85 during trading on Thursday, reaching $142.69. The company’s stock had a trading volume of 1,072,600 shares, compared to its average volume of 1,138,084. Shire PLC has a 12 month low of $137.17 and a 12 month high of $192.15. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55. The company has a market cap of $43,423.72, a P/E ratio of 9.94, a PEG ratio of 0.80 and a beta of 1.59.

Shire (NASDAQ:SHPG) last posted its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.64 by $0.17. Shire had a return on equity of 14.41% and a net margin of 10.95%. The business had revenue of $3.70 billion for the quarter. During the same period in the previous year, the company posted $3.17 EPS. Shire’s quarterly revenue was up 7.1% compared to the same quarter last year. equities analysts anticipate that Shire PLC will post 15 EPS for the current year.

TRADEMARK VIOLATION WARNING: This news story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/12/07/mr-capital-management-inc-purchases-706-shares-of-shire-plc-shpg.html.

Shire Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Institutional Ownership by Quarter for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.